LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

Singular Genomics Systems to Present at the Goldman Sachs Global Healthcare Conference

June 01, 2023 | Last Trade: US$20.01 0.00 0.00

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

Singular Genomics’ management is scheduled to participate in a fireside chat Tuesday, June 13, 2023, at 11:20 a.m. Pacific Time / 2:20 p.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com, in the News & Events section.

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.

Investor Contact

Matt Clawson
949-370-8500
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact

Dan Budwick, 1AB
973-271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page